FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD
Psychiatric Times
JULY 1, 2025
Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur. Clinical trials reveal higher plasma exposure and adverse effects in younger children, questioning the benefit-risk balance of these medications.
Let's personalize your content